What Post-Therapy SPECT/CT Reveals About ¹⁷⁷Lu-PSMA-617: Interim Disease Changes and the Case for Dynamic Monitoring
Predicting ¹⁷⁷Lu-Dotatate Retention: What Individual Pharmacokinetic Variability Means for PRRT Monitoring
What Urine Pharmacokinetics Can Teach Us: General Observations on Therapeutic Monitoring and Precision Medicine
